Optimistic Buy Rating for Acurx Pharmaceuticals Driven by Promising Developments and Financial Strength
Acurx Pharmaceuticals received a Buy rating from analyst Matthew Keller of H.C. Wainwright, with a price target of $31.00. This positive outlook is driven by significant developments in the company's lead compound, ibezapolstat (IBZ), including increased visibility through publications and presentations. Acurx is also exploring financing opportunities to expedite IBZ's development, supported by a recent warrant exercise that boosted cash reserves. Preclinical data presented at IDWeek ’25 showcased IBZ's unique properties, enhancing its potential in treating challenging bacterial infections.
Acurx Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Matthew Keller from H.C. Wainwright reiterated a Buy rating on the stock and has a $31.00 price target.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Matthew Keller’s rating is based on several promising developments at Acurx Pharmaceuticals. The company has made significant strides in increasing the visibility of its lead compound, ibezapolstat (IBZ), through recent publications and presentations. This has helped raise awareness in both private and public sectors, which is crucial for its late-stage clinical development.
Additionally, Acurx is actively exploring financing and partnering opportunities to expedite the development of IBZ. The company’s financial position is bolstered by a recent warrant exercise, adding to its cash reserves. Furthermore, preclinical data presented at IDWeek ’25 highlighted IBZ’s unique microbiome-sparing properties, which could enhance its efficacy in treating difficult bacterial infections. These factors collectively contribute to Keller’s optimistic outlook and Buy rating for Acurx Pharmaceuticals.
